Fatty Acid Binding Proteins Expressed at the Human Blood-Brain Barrier Bind Drugs in an Isoform-Specific Manner

Pharmaceutical Research

Volumn 32, Issue 10, 2015, Pages 3432-3446

  Lee, Gordon S ^a   Kappler, Katharina ^a   Porter, Christopher J H ^a   Scanlon, Martin J ^a   Nicolazzo, Joseph A ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

blood brain barrier; drug binding; expression profiles; fatty acid binding proteins; fluorescence displacement

Indexed keywords

2 [4 [2 [3 CYCLOHEXYL 1 (4 CYCLOHEXYLBUTYL)UREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; 8 ANILINO 1 NAPHTHALENESULFONIC ACID; BEZAFIBRATE; CLOFIBRIC ACID; DIAZEPAM; DRUG; FATTY ACID BINDING PROTEIN; FENOFIBRIC ACID; GEMFIBROZIL; GLITAZONE DERIVATIVE; IBUPROFEN; LIPOPHILIC DRUG; MEFENAMIC ACID; MESSENGER RNA; NITRAZEPAM; PIOGLITAZONE; RETINOIC ACID; ROSIGLITAZONE; TOLFENAMIC ACID; TROGLITAZONE; UNCLASSIFIED DRUG; 1-ANILINO-8-NAPHTHALENESULFONATE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; FENAMIC ACID DERIVATIVE; FIBRIC ACID DERIVATIVE; FLUORESCENT DYE; ISOPROTEIN; PROTEIN BINDING;

ARTICLE; BLOOD BRAIN BARRIER; CAPILLARY ENDOTHELIAL CELL; CONTROLLED STUDY; DRUG BINDING; ESCHERICHIA COLI; FLUORESCENCE ANALYSIS; GENE EXPRESSION; HUMAN; HUMAN CELL; INVESTIGATIVE PROCEDURES; LIPOPHILICITY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; BRAIN; CELL LINE; ENDOTHELIUM CELL; METABOLISM; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANILINO NAPHTHALENESULFONATES; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; CELL LINE; ENDOTHELIAL CELLS; FATTY ACID-BINDING PROTEINS; FENAMATES; FIBRIC ACIDS; FLUORESCENT DYES; HUMANS; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; PROTEIN ISOFORMS; RNA, MESSENGER; THIAZOLIDINEDIONES;

EID: 84942297688     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-015-1764-5     Document Type: Article

References (45)

1. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37:13-25.
2. Banks W. Drug transport into the central nervous system: using newer findings about the blood-brain barriers. Drug Deliv Transl Res. 2012;2:152-9.
3. Loscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol. 2005;76:22-76.
4. Pajouhesh H, Lenz GR. Medicinal chemical properties of successful central nervous system drugs. NeuroRx. 2005;2:541-53.
5. Urquhart BL, Kim RB. Blood-brain barrier transporters and response to CNS-active drugs. Eur J Clin Pharmacol. 2009;65:1063-70.
6. Martinez MN, Amidon GL. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Pharmacol Clin Toxicol. 2002;42:620-43.
7. Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab. 2012;32:1959-72.
8. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2:3-14.
9. Velkov T, Horne J, Laguerre A, Jones E, Scanlon MJ, Porter CJ. Examination of the role of intestinal fatty acid-binding protein in drug absorption using a parallel artificial membrane permeability assay. Chem Biol. 2007;14:453-65.
10. Velkov T. Thermodynamics of lipophilic drug binding to intestinal fatty acid binding protein and permeation across membranes. Mol Pharm. 2009;6:557-70.
11. Luxon BA, Milliano MT. Cytoplasmic transport of fatty acids in rat enterocytes: role of binding to fatty acid-binding protein. Am J Physiol. 1999;277(2 Pt 1):G361-6.
12. Zimmerman AW, Veerkamp JH. New insights into the structure and function of fatty acid-binding proteins. Cell Mol Life Sci. 2002;59:1096-116.
13. Bass NM, Manning JA. Tissue expression of three structurally different fatty acid binding proteins from rat heart muscle, liver, and intestine. Biochem Biophys Res Commun. 1986;137:929-35.
14. Hohoff C, Borchers T, Rustow B, Spener F, van Tilbeurgh H. Expression, purification, and crystal structure determination of recombinant human epidermal-type fatty acid binding protein. Biochemistry. 1999;38:12229-39.
15. He Y, Yang X, Wang H, Estephan R, Francis F, Kodukula S, et al. Solution-state molecular structure of apo and oleate-liganded liver fatty acid-binding protein. Biochemistry. 2007;46:12543-56.
16. Thompson J, Reese-Wagoner A, Banaszak L. Liver fatty acid binding protein: species variation and the accommodation of different ligands. Biochim Biophys Acta. 1999;23:1117-30.
17. Chuang S, Velkov T, Horne J, Porter CJ, Scanlon MJ. Characterization of the drug binding specificity of rat liver fatty acid binding protein. J Med Chem. 2008;51:3755-64.
18. Trevaskis NL, Nguyen G, Scanlon MJ, Porter CJ. Fatty acid binding proteins: potential chaperones of cytosolic drug transport in the enterocyte? Pharm Res. 2011;28:2176-90.
19. Velkov T, Lim ML, Horne J, Simpson JS, Porter CJ, Scanlon MJ. Characterization of lipophilic drug binding to rat intestinal fatty acid binding protein. Mol Cell Biochem. 2009;326:87-95.
20. Liu JW, Almaguel FG, Bu L, De Leon DD, De Leon M. Expression of E-FABP in PC12 cells increases neurite extension during differentiation: involvement of n-3 and n-6 fatty acids. J Neurochem. 2008;106:2015-29.
21. Mitchell RW, On NH, Del Bigio MR, Miller DW, Hatch GM. Fatty acid transport protein expression in human brain and potential role in fatty acid transport across human brain microvessel endothelial cells. J Neurochem. 2011;117:735-46.
22. Weksler BB, Subileau EA, Perriere N, Charneau P, Holloway K, Leveque M, et al. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 2005;19:1872-4.
23. Froger A, Hall JE. Transformation of plasmid DNA into E. coli using the heat shock method. J Vis Exp. 2007;6:253.
24. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973;22:3099-108.
25. Tjernberg A, Markova N, Griffiths WJ, Hallen D. DMSO-related effects in protein characterization. J Biomol Screen. 2006;11:131-7.
26. Sheng N, Li J, Liu H, Zhang A, Dai J. Interaction of perfluoroalkyl acids with human liver fatty acid-binding protein. Arch Toxicol. 2014;290:13895 - 906.
27. Richieri GV, Ogata RT, Zimmerman AW, Veerkamp JH, Kleinfeld AM. Fatty acid binding proteins from different tissues show distinct patterns of fatty acid interactions. Biochemistry. 2000;39:7197-204.
28. Kleinfeld AM, Chu P, Romero C. Transport of long-chain native fatty acids across ipid bilayer membranes indicates that transbilayer flip-flop is rate limiting. Biochemistry. 1997;36:14146-58.
29. Patil R, Laguerre A, Wielens J, Headey SJ, Williams ML, Hughes ML, et al. Characterization of two distinct modes of drug binding to human intestinal fatty acid binding protein. ACS Chem Biol. 2014;9:2526-34.
30. Pelerin H, Jouin M, Lallemand MS, Alessandri JM, Cunnane SC, Langelier B, et al. Gene expression of fatty acid transport and binding proteins in the blood-brain barrier and the cerebral cortex of the rat: differences across development and with different DHA brain status. Prostaglandins Leukot Essent Fat Acids. 2014;91:213-20.
31. Hagberg C, Mehlem A, Falkevall A, Muhl L, Eriksson U. Endothelial fatty acid transport: role of vascular endothelial growth factor B. Physiology. 2013;28:125-34.
32. Bachmeier C, Mullan M, Paris D. Characterization and use of human brain microvascular endothelial cells to examine beta-amyloid exchange in the blood-brain barrier. Cytotechnology. 2010;62:519-29.
33. Balendiran GK, Schnutgen F, Scapin G, Borchers T, Xhong N, Lim K, et al. Crystal structure and thermodynamic analysis of human brain fatty acid-binding protein. J Biol Chem. 2000;275:27045-54.
34. Thompson J, Winter N, Terwey D, Bratt J, Banaszak L. The crystal structure of the liver fatty acid-binding protein. A complex with two bound oleates. J Biol Chem. 1997;272:7140-50.
35. Scapin G, Young AM, Kromminga A, Veerkamp J, Gordon J, Sacchettini J. High resolution X-ray studies of mammalian intestinal and muscle fatty acid-binding proteins provide an opportunity for defining the chemical nature of fatty acid: protein interactions. Mol Cell Biochem. 1993;123:3-13.
36. Hirose M, Sugiyama S, Ishida H, Niiyama M, Matsuoka D, Hara T, et al. Structure of the human-heart fatty-acid-binding protein 3 in complex with the fluorescent probe 1-ranilinonaphthalene-8-sulphonic acid. J Synchrotron Radiat. 2013;20:923-8.
37. Gillilan RE, Ayers SD, Noy N. Structural basis for activation of fatty acid-binding protein 4. J Mol Biol. 2007;372:1246-60.
38. Gutierrez-Gonzalez LH, Ludwig C, Hohoff C, Rademacher M, Hanhoff T, Ruterjans H, et al. Solution structure and backbone dynamics of human epidermal-type fatty acid-binding protein (E-FABP). Biochem J. 2002;364:725-37.
39. Zimmerman AW, Rademacher M, Ruterjans H, Lucke C, Veerkamp JH. Functional and conformational characterization of new mutants of heart fatty acid-binding protein. Biochem J. 1999;344(Pt 2):495-501.
40. Velkov T. Interactions between human liver fatty acid binding protein and peroxisome proliferator activated receptor selective drugs. PPAR Res. 2013; 938401.
41. Kane CD, Bernlohr DA. A simple assay for intracellular lipid-binding proteins using displacement of 1-anilinonaphthalene 8-sulfonic acid. Anal Biochem. 1996;233:197-204.
42. Richieri GV, Ogata RT, Kleinfeld AM. Fatty acid interactions with native and mutant fatty acid binding proteins. Mol Cell Biochem. 1999;192:77-85.
43. Bergstrom CA, Charman SA, Nicolazzo JA. Computational prediction of CNS drug exposure based on a novel in vivo dataset. Pharm Res. 2012;29:3131-42.
44. Hughes ML, Liu B, Halls ML, Wagstaff KM, Patil R, Velkov T, et al. Fatty acid binding proteins 1 and 2 differentially modulate the activation of peroxisome proliferator-activated receptor alpha in a ligand-selective manner. J Biol Chem. 2015.[In Press]
45. Tan NS, Shaw NS, Vinckenbosch N, Liu P, Yasmin R, Desvergne B, et al. Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription. Mol Cell Biol. 2002;22(14):5114-27.